Agaricus blazei and insulin resistance and the liver. We describe studies involving humans, including reports of severe liver damage in cancer patients.

A meta-analysis of twelve studies separates what is usually lumped together: sleep quality, insomnia, situational anxiety, and generalized anxiety. The results vary.

A 167 percent increase in sperm concentration sounds impressive, but it is calculated against the baseline. We check what was actually measured and against what.

Phase 3 studies MAPP1 and MAPP2 measured the effect of MDMA-assisted therapy in PTSD. We check what their numbers mean and why the FDA refused registration.

Dabbing is the vaporization of concentrate on a heated bowl. Measured temperatures, decomposition products, differences compared to vaporizing flower, and the legal status in Poland.

Common motherwort without myths: the status of the EMA monograph, indication for palpitations of nervous origin, clinical trial results, and a complete list of contraindications.

Two studies from 2016 and 80 oncology patients: what was really measured, with what scales, at what point in time, and what these results do not resolve at all.

The Johns Hopkins studies and the COMPASS trials measured the effect of psilocybin in depression. We check which results come from phase 2 and what is known about phase 3.

Pharmacokinetics, 5-HT2A receptor, and cycle: what studies on psychedelics say about women, and what, contrary to popular belief, has not yet been published even once.

Phase 3 studies on MDMA, the FDA's refusal in 2024, and pilot studies with psilocybin in veterans. How many people, what numbers, and how many veterans were actually in these trials.

The default mode network (DMN) and afterglow: what was actually measured in psilocybin studies, how long the effects lasted, and what was not shown.

What are psychoplastogens, how do psychedelics interact with the TrkB receptor, and how does this change our understanding of depression? A review of studies from Nature Neuroscience and Science.